These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 5608556)

  • 1. [Effect of the anticoagulant nafarin on the course of ischemic disease of the myocardium].
    Semeniuk AV
    Sov Med; 1967 Apr; 30(4):101-4. PubMed ID: 5608556
    [No Abstract]   [Full Text] [Related]  

  • 2. Potentiation of anticoagulant effect of warfarin by phenylbutazone.
    Aggeler PM; O'Reilly RA; Leong L; Kowitz PE
    N Engl J Med; 1967 Mar; 276(9):496-501. PubMed ID: 6018280
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of the anticoagulant nafarin on the immunological reactivity].
    Kovalev IE; Lakin KM
    Farmakol Toksikol; 1967; 30(6):696-9. PubMed ID: 5598440
    [No Abstract]   [Full Text] [Related]  

  • 4. [Interaction between anticoagulants and indomethacin].
    Odegaard AE
    Tidsskr Nor Laegeforen; 1974 Nov; 94(33):2313-4. PubMed ID: 4439389
    [No Abstract]   [Full Text] [Related]  

  • 5. Thrombolytic therapy in patients with an abnormality of blood coagulation.
    St John G; Talley JD
    J Ark Med Soc; 1995 Jul; 92(2):81-2. PubMed ID: 7642479
    [No Abstract]   [Full Text] [Related]  

  • 6. Factor VII during warfarin treatment.
    Howarth DJ; Brozović M; Stirling Y; Reed M
    Scand J Haematol; 1974; 12(5):346-54. PubMed ID: 4859330
    [No Abstract]   [Full Text] [Related]  

  • 7. [Case of polycythemia vera associated with myocardial infarction and cerebral thrombosis and treated by anticoagulant therapy].
    Sawada K; Shmizu M; Konno T; Shibaki H; Sakurama S
    Rinsho Ketsueki; 1983 Feb; 24(2):191-6. PubMed ID: 6655878
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of coronary insufficiency with nafarin].
    Zhivoderov VM; Pin'kevich NM
    Kardiologiia; 1966; 6(1):68-9. PubMed ID: 5970409
    [No Abstract]   [Full Text] [Related]  

  • 9. Dietary related plasma vitamin C concentration has no effect on anticoagulation response to warfarin.
    Wynne H; Khan T; Avery P; Wood P; Ward A; Kamali F
    Thromb Res; 2006; 118(4):501-4. PubMed ID: 16139332
    [No Abstract]   [Full Text] [Related]  

  • 10. Programmed instruction as a patient teaching tool: a study of myocardial infarction patients receiving warfarin.
    Rankin MA
    Heart Lung; 1979; 8(3):511-6. PubMed ID: 254673
    [No Abstract]   [Full Text] [Related]  

  • 11. The effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus.
    Douketis JD; Crowther MA; Julian JA; Stewart K; Donovan D; Kaminska EA; Laskin CA; Ginsberg JS
    Thromb Haemost; 1999 Sep; 82(3):1028-32. PubMed ID: 10494759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of warfarin by acetaminophen.
    Brown D
    J Fam Pract; 1998 Jun; 46(6):456-7. PubMed ID: 9638105
    [No Abstract]   [Full Text] [Related]  

  • 13. Anticoagulant therapy in myocardial infarction.
    Vigran IM
    Geriatrics; 1967 Jul; 22(7):89-100. PubMed ID: 6027050
    [No Abstract]   [Full Text] [Related]  

  • 14. Anticoagulant therapy in myocardial infarction.
    Seaman AJ; Griswold HE; Reaume RB; Ritzmann L
    N Engl J Med; 1969 Sep; 281(13):738-9. PubMed ID: 5821170
    [No Abstract]   [Full Text] [Related]  

  • 15. Lack of effect of influenza immunisation on anticoagulant control in patients on long-term warfarin.
    MacCallum P; Madhani M; Mt-Isa S; Ashby D
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):786-9. PubMed ID: 17111459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contribution of plasma (R)- & (S)-warfarin and vitamin K concentrations to intra-individual variability in anticoagulation.
    Kamali F; Edwards C; Butler TJ; Wynne HA
    Thromb Haemost; 2000 Feb; 83(2):349-50. PubMed ID: 10739399
    [No Abstract]   [Full Text] [Related]  

  • 18. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment.
    Brodin E; Seljeflot I; Arnesen H; Hurlen M; Appelbom H; Hansen JB
    Thromb Res; 2009 Feb; 123(4):573-9. PubMed ID: 18474393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice.
    Caro JJ; Flegel KM; Orejuela ME; Kelley HE; Speckman JL; Migliaccio-Walle K
    CMAJ; 1999 Sep; 161(5):493-7. PubMed ID: 10497604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT).
    Chesney CM; Elam MB; Herd JA; Davis KB; Garg R; Hunninghake D; Kennedy JW; Applegate WB
    Am Heart J; 2000 Oct; 140(4):631-6. PubMed ID: 11011338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.